Intervention
Oxytocin
ClinicalTrials.gov intervention label
Explore related research
Search across original and mapped recordsSearch results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 52 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
52 shownOxytocin-Augmented Group Psychotherapy for Patients With Schizophrenia - an Oxytocin-dose ComparisonNCT07265180 · 2025-09-08
RECRUITINGEffect of Ephedrine, Phenylepinephrine, and Norepinephrine on Myometrial Contractility in Pregnant People With Type II and Gestational Diabetes During Cesarean Section: An In-vitro StudyNCT06285396 · 2024-03-18
RECRUITINGThe Role of Oxytocin in Regulating Blood GlucoseNCT06334172 · 2024-01-01
RECRUITINGThe Effect of Oxytocin on the Alpha Cell Response to Hypoglycaemia in Patients With Type 1 DiabetesNCT06881459 · 2025-03-25
COMPLETEDThe Role of Oxytocin-receptor Signalling in Physiological Regulation of Eating Behaviour in Individuals with ObesityNCT06189001 · 2024-01-01
COMPLETEDOXYMIND: Oxytocin-augmented Group Psychotherapy for Patients With SchizophreniaNCT06136390 · 2023-09-30
COMPLETEDMethods Decreasing Bleeding in Open MyomectomyNCT05806307 · 2023-03-15
UNKNOWNThe Association of Affective Resonance With Empathy Modulated by Negative Symptomatology and OxytocinNCT05247151 · 2021-08-02
COMPLETEDOxytocin vs Carbetocin at Cesarean Delivery in Women With Morbid ObesityNCT04902729 · 2021-07-20
COMPLETEDEffects of Oxytocin and Vasopressin on Moral Decision MakingNCT04890470 · 2021-03-02
COMPLETEDA Pharmaco-imaging Approach to Predicting Social Functioning and Clinical Responses to Oxytocin Administration in SchizophreniaNCT03900754 · 2020-01-13
TERMINATEDPre-operative Intranasal Oxytocin for Enhancing Bariatric-induced Diabetes RemissionNCT05207774 · 2020-01-09
UNKNOWNA Randomized Trial of Oral Misoprostol Alone Versus Oral Misoprostol Followed by Oxytocin for Labour InductionNCT03749902 · 2020-01-06
COMPLETEDNeurobiological Effects of Oxytocin in SchizophreniaNCT04177719 · 2019-11-08
UNKNOWNqMOLI- A Qualitative Assessment of Misoprostol or Oxytocin for Labour InductionNCT04037683 · 2019-10-18
COMPLETEDOxytocin at Elective Cesarean Deliveries: A Dose-finding Study in Women With BMI ≥ 40kg/m2NCT03957083 · 2019-06-26
COMPLETEDHigh Dose Versus Low Dose Oxytocin for Augmentation of Delayed Labour in Obese WomenNCT03604874 · 2018-09-01
COMPLETEDEffects of Oxytocin on Negative Symptoms and Social Cognition in Schizophrenia and Its Possible MechanismsNCT03662425 · 2018-07-21
COMPLETEDDifferential Effects of Vasopressin and Oxytocin on Attention ControlNCT04715737 · 2017-12-19
COMPLETEDIntranasal Oxytocin for Infants With Prader-Willi SyndromeNCT03245762 · 2017-08-01
COMPLETEDOxytocin Dosage to Decrease Induction DurationNCT03140488 · 2017-06-05
COMPLETEDFollow-up of Prader Willi Syndrome Infants Treated by Oxytocin and Comparison With Not-treated Infants.NCT03081832 · 2017-01-01
COMPLETEDOxytocin HIV Meth StudyNCT02881177 · 2017-01-01
COMPLETEDOxytocin Intranasal Administrations in Children With Prader-Willi Syndrome Aged From 3 to 12 YearsNCT03114371 · 2016-11-28
COMPLETEDPostpartum Hemorrhage Prevention in Patients With Preeclampsia (PHP3 Study)NCT02221830 · 2015-02-01
COMPLETEDOxytocin Effects on Food Motivation PathwaysNCT02276677 · 2014-10-01
COMPLETEDNeurobiological Bases of Paternal NurturanceNCT02223429 · 2014-08-01
COMPLETEDEffects of Intranasal Administration of Oxytocin in Adults With Prader-Willi SyndromeNCT02804373 · 2014-06-01
COMPLETEDOxytocin as Adjunctive Therapy for SchizophreniaNCT01699997 · 2014-01-01
COMPLETEDIn-vitro Myometrial Contractility After Oxytocin Pre-exposure in Women With Advanced Maternal Age and Morbid ObesityNCT01865669 · 2013-05-01
COMPLETEDOxytocin as Adjunctive Treatment of SchizophreniaNCT01568528 · 2013-03-01
COMPLETEDAdult Study Oxytocin - fMRINCT02566356 · 2012-09-01
COMPLETEDEffects of Intranasal Oxytocin on Satiety Signaling in People With SchizophreniaNCT01614093 · 2012-06-01
COMPLETEDAdministrating Oxytocin to Treat Treatment Schizophrenia and Schizo-affective PatientsNCT01598623 · 2012-05-01
UNKNOWNOxytocin MEG StudyNCT02568709 · 2012-02-01
COMPLETEDPharmacological Approach to Improve the Outcome of Social Cognition TrainingNCT01517360 · 2012-01-01
COMPLETEDOxytocin and Tibolone Adjuncts in Treatment Resistant Depression - A Pilot StudyNCT01239888 · 2012-01-01
UNKNOWNCarbetocin vs. Oxytocin for Prevention of Postpartum Bleeding in Patients With Severe PreeclampsiaNCT01382732 · 2012-01-01
UNKNOWNTolerance of Intranasal Administration of OT in Prader-Willi Newborn BabiesNCT01548521 · 2011-07-01
COMPLETEDAntipsychotic Effects of OxytocinNCT01621737 · 2011-06-01
TERMINATEDDoes Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?NCT01312272 · 2011-04-01
COMPLETEDEffects of Intranasal Oxytocin and Vasopressin on Social BehaviorNCT01296269 · 2011-04-01
UNKNOWNDyad Oxytocin Study (DOS)NCT02302209 · 2011-04-01
COMPLETEDAdult Study Oxytocin - BehavioralNCT02567032 · 2010-10-01
COMPLETEDOxytocin Add-on for Stable Depressed PatientsNCT01211756 · 2010-10-01
TERMINATEDAdult Oxytocin StudyNCT02577575 · 2010-08-01
COMPLETEDBrain Blood Flow Changes Elicited by Oxytocin in Volunteers With and Without SchizophreniaNCT01123317 · 2010-07-01
WITHDRAWNBrain Imaging Study of Adults With Autism Spectrum DisordersNCT01093768 · 2010-02-19
COMPLETEDOxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in SchizophreniaNCT01012167 · 2010-02-01
COMPLETEDOxytocin and Social Cognition in SchizophreniaNCT00884897 · 2010-01-01
COMPLETEDEffects of Oxytocin Nasal Spray on Social AffiliationNCT00663039 · 2009-10-01
COMPLETEDOxytocin Add on Study for Stable Schizophrenic PatientsNCT00506909 · 2008-03-01
TERMINATEDCommon conditions
Schizophrenia18Oxytocin5Prader-Willi Syndrome5Social Cognition5Healthy4Postpartum Hemorrhage4Obesity3Major Depressive Disorder2Schizophrenia Spectrum Disorders2Adiposity1Amphetamine Use Disorders1Autism Spectrum Disorder1Autism Spectrum Disorders1Bariatric Surgery1Blood Loss, Surgical1DELAYED LABOUR1Depression1Diabetes1Dysthymia Disorder1Emotional Intelligence1Ethamsylate Allergy1Functional Magnetic Resonance Imaging (fMRI)1Glucose Metabolism Disorders (Including Diabetes Mellitus)1Induction of Labor1Labor, Induced1
Mapped diseases appearing in these trials
Shared study participation does not establish that this intervention treats a disease.
Leading sponsors
University of California, San Francisco
6
University of Maryland, Baltimore
5
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
4
University Hospital, Toulouse
4
Charite University, Berlin, Germany
3
University Hospital, Gentofte, Copenhagen
3
David Feifel
2
University of Electronic Science and Technology of China
2
University of Liverpool
2
VA Greater Los Angeles Healthcare System
2
Assiut University
1
Cairo University
1
Emory University
1
Hadassah Medical Organization
1
IRCCS Centro San Giovanni di Dio Fatebenefratelli
1
Trial status mix
COMPLETED37
UNKNOWN7
TERMINATED4
RECRUITING3
WITHDRAWN1
Phase mix
NA24
PHASE210
PHASE17
EARLY_PHASE16
PHASE45
PHASE32
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.